🚀 VC round data is live in beta, check it out!
Progyny Valuation Multiples
Discover revenue and EBITDA valuation multiples for Progyny and similar public comparables like Pluxee, Clover Health, Hapvida, GoodRx and more.
Progyny Overview
About Progyny
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Founded
2008
HQ
Employees
680
Website
Financials (LTM)
EV
$1B
Progyny Financials
Progyny reported last 12-month revenue of $1B and EBITDA of $224M.
In the same LTM period, Progyny generated $324M in gross profit, $224M in EBITDA, and $68M in net income.
Revenue (LTM)
Progyny P&L
In the most recent fiscal year, Progyny reported revenue of $1B and EBITDA of $222M.
Progyny expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Profit | $324M | XXX | $304M | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA | $224M | XXX | $222M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $68M | XXX | $59M | XXX | XXX | XXX |
| Net Margin | 5% | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Progyny Stock Performance
Progyny has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Progyny's stock price is $17.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | 0.0% | XXX | XXX | XXX | $0.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProgyny Valuation Multiples
Progyny trades at 0.9x EV/Revenue multiple, and 5.2x EV/EBITDA.
EV / Revenue (LTM)
Progyny Financial Valuation Multiples
As of March 17, 2026, Progyny has market cap of $1B and EV of $1B.
Equity research analysts estimate Progyny's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Progyny has a P/E ratio of 21.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 0.9x | XXX | 0.9x | XXX | XXX | XXX |
| EV/EBITDA | 5.2x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBIT | 5.3x | XXX | 5.3x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 21.4x | XXX | 24.7x | XXX | XXX | XXX |
| EV/FCF | 6.2x | XXX | 6.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Progyny Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Progyny Margins & Growth Rates
Progyny's revenue in the last 12 month grew by 7%.
Progyny's revenue per employee in the last FY averaged $1.9M.
Progyny's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Progyny's rule of X is 36% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Progyny Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 5% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 25% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 36% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 6% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | 11% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Progyny Public Comps
See public comps and valuation multiples for other Health Benefits & Financial Solutions comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Pluxee | XXX | XXX | XXX | XXX | XXX | XXX |
| Clover Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Hapvida | XXX | XXX | XXX | XXX | XXX | XXX |
| GoodRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Evolent Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Progyny M&A Activity
Progyny acquired XXX companies to date.
Last acquisition by Progyny was on XXXXXXXX, XXXXX. Progyny acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Progyny
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProgyny Investment Activity
Progyny invested in XXX companies to date.
Progyny made its latest investment on XXXXXXXX, XXXXX. Progyny invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Progyny
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Progyny
| When was Progyny founded? | Progyny was founded in 2008. |
| Where is Progyny headquartered? | Progyny is headquartered in United States. |
| How many employees does Progyny have? | As of today, Progyny has over 680 employees. |
| Who is the CEO of Progyny? | Progyny's CEO is Peter Anevski. |
| Is Progyny publicly listed? | Yes, Progyny is a public company listed on Nasdaq. |
| What is the stock symbol of Progyny? | Progyny trades under PGNY ticker. |
| When did Progyny go public? | Progyny went public in 2019. |
| Who are competitors of Progyny? | Progyny main competitors are Pluxee, Clover Health, Hapvida, GoodRx. |
| What is the current market cap of Progyny? | Progyny's current market cap is $1B. |
| What is the current revenue of Progyny? | Progyny's last 12 months revenue is $1B. |
| What is the current revenue growth of Progyny? | Progyny revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Progyny? | Current revenue multiple of Progyny is 0.9x. |
| Is Progyny profitable? | Yes, Progyny is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Progyny? | Progyny's last 12 months EBITDA is $224M. |
| What is Progyny's EBITDA margin? | Progyny's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of Progyny? | Current EBITDA multiple of Progyny is 5.2x. |
| What is the current FCF of Progyny? | Progyny's last 12 months FCF is $186M. |
| What is Progyny's FCF margin? | Progyny's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Progyny? | Current FCF multiple of Progyny is 6.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.